AlphaMaven AlphaMaven

Exclusive: Thoma Bravo explores $3 billion-plus sale of software firm Apryse, sources say

Reported by Reuters
May 29, 2025· 2 min read
Save Post LinkedIn Email
Key Takeaways
  • • Thoma Bravo is exploring a sale of Apryse, a document processing software platform, valued at $3 billion or higher, with Lazard advising on the transaction and multiple private equity firms already expressing interest.
  • • Apryse generates over $100 million in annual EBITDA with growth exceeding 20% annually, translating to an expected valuation multiple of 30x EBITDA or higher at deal completion.
  • • Thoma Bravo acquired Apryse (formerly PDFTron) in 2021 and may retain a minority equity stake in any sale, indicating a potential continuation of upside participation post-exit.
  • • The company serves enterprise customers including Novartis, Wells Fargo, and DocuSign, with document processing capabilities spanning creation, editing, conversion, and application integration across mobile and computer platforms.
  • • No final decision has been made and no sale is guaranteed; sources cautioned that the process remains in exploratory stages with confidentiality restrictions in place.
Summary
Thoma Bravo, the Denver-based buyout firm, is actively exploring the sale of Apryse, its document processing software subsidiary, in a transaction expected to exceed $3 billion in enterprise value. Multiple private equity firms have already signaled interest in acquiring the asset, according to people familiar with the matter. Investment bankers at Lazard have been engaged to facilitate the sale process, with Thoma Bravo retaining the option to maintain a minority stake in Apryse as part of any definitive transaction structure.

Apryse presents an attractive acquisition target based on its financial profile and market position. The company generates more than $100 million in annual EBITDA while maintaining robust organic growth rates exceeding 20 percent year-over-year. Sources indicate that potential acquirers are pricing the company at a multiple of 30x EBITDA or higher, reflecting investor confidence in its revenue durability and expansion trajectory. The company has augmented its capabilities through more than a dozen strategic acquisitions designed to expand its product functionality and market reach.

The asset commands significant institutional customer relationships across diversified industry verticals. Apryse's document processing platform serves blue-chip customers including pharmaceutical leader Novartis, financial services giant Wells Fargo, and enterprise software provider DocuSign. The platform provides core functionality enabling developers to integrate document creation, editing, conversion, and processing capabilities into their own applications across mobile and desktop environments.

Thoma Bravo acquired the company (formerly known as PDFTron, which was founded in 1998) in 2021 under the investment leadership of Hudson Smith, co-head of Thoma Bravo's Discover platform. The current sale exploration represents a potential exit after approximately four years of ownership and value-creation efforts. However, sources emphasized that the process remains preliminary—no sale is guaranteed and final strategic decisions have not been finalized. Thoma Bravo, Apryse, and Lazard all declined or did not respond to requests for comment on the transaction.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Reuters Exclusive: Thoma Bravo explores $3 billion-plus sale of software firm Apryse, sources say